What are the guidelines for converting a patient from levothyroxine (T4) to liothyronine (T3)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Guidelines for Converting a Patient from Levothyroxine to Liothyronine

When converting a patient from levothyroxine (T4) to liothyronine (T3), the recommended approach is to start with a low dose of liothyronine and gradually increase while monitoring thyroid function, using an approximate conversion ratio of 3:1 (T4:T3 by weight).

Initial Assessment

  • Before conversion, confirm the indication for switching from levothyroxine to liothyronine, as levothyroxine remains the standard treatment for hypothyroidism 1
  • Evaluate current thyroid function with TSH, free T4, and free T3 levels to establish baseline status 2
  • Review patient's medical history for cardiac disease, osteoporosis, or other conditions that might increase risk with liothyronine therapy 3
  • Consider consulting with an endocrinologist before initiating conversion, especially for complex cases 1

Conversion Protocol

  • Discontinue levothyroxine and initiate liothyronine at a low starting dose 4
  • For mild hypothyroidism: Start with 25 mcg of liothyronine daily 4
  • For moderate to severe hypothyroidism: Consider starting with a lower dose of 5 mcg daily and increase gradually 4
  • For elderly patients or those with cardiovascular disease: Begin with 5 mcg daily and increase by 5 mcg increments at recommended intervals 4

Dosage Titration

  • Increase dosage by up to 25 mcg every 1-2 weeks for mild hypothyroidism 4
  • For moderate to severe cases, increase by 5-10 mcg daily every 1-2 weeks; when reaching 25 mcg daily, may increase by 5-25 mcg every 1-2 weeks 4
  • Usual maintenance dose ranges:
    • Mild hypothyroidism: 25-75 mcg daily 4
    • Myxedema: 50-100 mcg daily 4
    • Simple goiter: 75 mcg daily 4

Monitoring

  • Monitor thyroid function tests (TSH, free T4, free T3) 4-6 weeks after each dose adjustment 2
  • Target a normal TSH within reference range unless specific indications for TSH suppression exist (e.g., thyroid cancer) 3
  • Monitor for signs of hyperthyroidism: palpitations, anxiety, insomnia, weight loss, heat intolerance 2
  • Be aware that liothyronine has a more rapid onset and shorter half-life than levothyroxine, which may cause more pronounced cardiovascular side effects 4

Conversion Ratio Considerations

  • The pharmacodynamic equivalence between levothyroxine and liothyronine is approximately 3:1 by weight 5
  • For example, 100 mcg of levothyroxine would roughly equate to about 33 mcg of liothyronine 5
  • However, due to liothyronine's shorter half-life, the daily dose is often divided into two administrations 1

Special Considerations

  • Liothyronine has a rapid onset and dissipation of action compared to levothyroxine, leading to wider swings in serum T3 levels 4
  • Consider twice-daily dosing to minimize fluctuations in T3 levels 1
  • Patients with cardiac disease require more careful monitoring due to potential cardiovascular effects 3
  • Elderly patients should start with lower doses and increase more gradually 4

Potential Pitfalls

  • Avoid rapid dose escalation, which may precipitate cardiac symptoms, especially in elderly or those with cardiovascular disease 3
  • Be aware that the wide swings in serum T3 levels that follow liothyronine administration may counterbalance its advantages 4
  • Monitor closely for overtreatment, which can lead to subclinical or overt hyperthyroidism with risks of atrial fibrillation and bone loss 3
  • Remember that liothyronine is not recommended as first-line therapy for most hypothyroid patients 1

Indications for Liothyronine Preference

  • Impairment of peripheral conversion of T4 to T3 is suspected 4
  • During radioisotope scanning procedures (temporary use) 4
  • As a trial in patients who have persistent symptoms despite optimal levothyroxine therapy with normal TSH 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.